These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients. Odler B; Bikov A; Streizig J; Balogh C; Kiss E; Vincze K; Barta I; Horváth I; Müller V Lupus; 2017 May; 26(6):572-579. PubMed ID: 27614982 [TBL] [Abstract][Full Text] [Related]
4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209 [TBL] [Abstract][Full Text] [Related]
5. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672 [TBL] [Abstract][Full Text] [Related]
7. Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome. Deák M; Bocskai M; Burcsár S; Dányi O; Fekete Z; Kovács L Lupus; 2014 Aug; 23(9):913-8. PubMed ID: 24729279 [TBL] [Abstract][Full Text] [Related]
8. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Perez-Sanchez C; Barbarroja N; Messineo S; Ruiz-Limon P; Rodriguez-Ariza A; Jimenez-Gomez Y; Khamashta MA; Collantes-Estevez E; Cuadrado MJ; Aguirre MA; Lopez-Pedrera C Ann Rheum Dis; 2015 Jul; 74(7):1441-9. PubMed ID: 24618261 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value and predictors of the alteration of the diffusing capacity of the lungs for carbon monoxide in systemic lupus erythematosus. Le Tallec E; Bourg C; Bouzillé G; Belhomme N; Le Pabic E; Guillot S; Droitcourt C; Perlat A; Jouneau S; Donal E; Lescoat A Rheumatology (Oxford); 2024 Aug; 63(8):2178-2188. PubMed ID: 37831905 [TBL] [Abstract][Full Text] [Related]
10. Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome. Paran D; Caspi D; Levartovsky D; Elkayam O; Kaufman I; Litinsky I; Keren G; Koifman B Ann Rheum Dis; 2007 Apr; 66(4):506-10. PubMed ID: 17079247 [TBL] [Abstract][Full Text] [Related]
11. Single-breath pulmonary diffusing capacity. Reference values and application in connective tissue diseases and in various lung diseases. Salorinne Y Scand J Respir Dis Suppl; 1976; 96():1-84. PubMed ID: 1076826 [TBL] [Abstract][Full Text] [Related]
14. Thin-section chest CT findings in systemic lupus erythematosus with antiphospholipid syndrome: a comparison with systemic lupus erythematosus without antiphospholipid syndrome. Oki H; Aoki T; Saito K; Yamashita Y; Hanamiya M; Hayashida Y; Tanaka Y; Korogi Y Eur J Radiol; 2012 Jun; 81(6):1335-9. PubMed ID: 21501937 [TBL] [Abstract][Full Text] [Related]
15. Comparison of lung perfusion scintigraphic findings in pulmonary thromboembolism in systemic lupus erythematosus, SLE plus antiphospholipid syndrome, and primary antiphospholipid syndrome. Aung W; Murata Y; Ishida R; Shibuya H Nucl Med Commun; 2000 Mar; 21(3):299-304. PubMed ID: 10823333 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and reversibility of pulmonary dysfunction in refractory systemic lupus: improvement correlates with disease remission following hematopoietic stem cell transplantation. Traynor AE; Corbridge TC; Eagan AE; Barr WG; Liu Q; Oyama Y; Burt RK Chest; 2005 May; 127(5):1680-9. PubMed ID: 15888846 [TBL] [Abstract][Full Text] [Related]
17. [Clinical and morphological characteristics of lupus nephritis in systemic lupus erythematosus with antiphospholipid syndrome]. Kozlovskaia NL; Shilov EM; Meteleva NA; Varshavskiĭ VA; Miroshnichenko NG; Samokishina NA; Serova AG; Nesterova SG Ter Arkh; 2006; 78(5):21-31. PubMed ID: 16889045 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and pattern of antiphospholipid antibody syndrome in a hospital based longitudinal study of 193 patients of systemic lupus erythematosus. Singh NK; Agrawal A; Singh MN; Kumar V; Godhra M; Gupta A; Yadav DP; Usha ; Singh RG; Singh TB J Assoc Physicians India; 2013 Sep; 61(9):623-6. PubMed ID: 24772699 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary dysfunction in systemic lupus erythematosus without pulmonary symptoms. Chick TW; DeHoratius RJ; Skipper BE; Messner RP J Rheumatol; 1976 Sep; 3(3):262-8. PubMed ID: 1086364 [TBL] [Abstract][Full Text] [Related]
20. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. Danowski A; de Azevedo MN; de Souza Papi JA; Petri M J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]